UK launches £20m organoid project to replace animal drug testing with human tissue models

Britain is about to grow human organs the size of a grain of sand. These miniature tissues, cultivated from patient cells supplied by the NHS, will become the new testing ground for experimental drugs—a fundamental shift away from the animals that have long served as stand-ins for human disease. The effort is anchored by a £20 million research hub at Cambridge, tasked with building a library of standardized organoids that pharmaceutical companies and academic researchers can draw from to test whether new medicines actually work before they ever reach a person.

The science itself is not new. For more than a decade, researchers have been coaxing human cells into forming tiny clumps that behave like organs. A piece smaller than a millimetre can replicate how a full-scale organ functions, how it breaks down under disease, and crucially, how it responds to drugs. What is new is the scale and ambition: turning these laboratory curiosities into a systematic, validated resource that can replace the traditional animal model.

The problem with animal testing is stark and well-documented. More than 90 percent of drugs that pass safety tests in animals fail when given to humans. Mice, rats, and other creatures do not get human diseases in the way humans do. A condition that appears in a mouse may manifest entirely differently in a person, or not appear at all. Matthias Zilbauer, a clinical professor of paediatric gastroenterology at Cambridge, puts it plainly: a mouse cannot tell you which treatments work for which patients. An organoid grown from a patient's own diseased tissue can.

The Cambridge hub will begin with organoids modeled on inflammatory bowel diseases like ulcerative colitis and Crohn's disease. Other teams will grow cancerous organoids to refine cancer treatments, and brain organoids to unlock neurological conditions. The organoids will be made available to both industry and academia, creating a shared resource that accelerates drug development while reducing the number of animals needed in the pipeline. Zilbauer acknowledges that animal testing will not disappear entirely—there are still questions that organoids cannot answer—but the reduction will be substantial.

The government's commitment reflects a broader strategy to phase out animal testing through what regulators call "new approach methodologies." These include not just organoids but also organ-on-chip systems, where human tissues are grown on microfluidic devices, and artificial intelligence tools that can process biological data and model how drugs behave in living systems. Last year, Britain conducted 2.54 million animal testing procedures, down 3.8 percent from the year before. More than 90 percent involved mice, rats, fish, and birds, though one percent involved specially protected species—cats, dogs, horses, and monkeys.

An additional £2 million from Innovate UK is funding nine separate projects aimed specifically at reducing the use of dogs and primates in safety testing. One company, VivoSphere, is growing heart cells inside tiny gel spheres to test whether drugs damage the heart. Traditionally, such tests require 50 to 100 animals—guinea pigs, rabbits, dogs. By detecting toxicity earlier, in human tissue, harmful drugs never reach the animal testing stage. The logic is simple: if a drug is going to fail, it is better to know before animals are exposed to it, and better still before patients are.

What organoids represent is a return to first principles. Instead of asking whether a drug works in a mouse, researchers will ask whether it works in human tissue taken from the people who actually need the treatment. The answer will be more reliable, more humane, and ultimately more useful for medicine.